About Design Therapeutics
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. The Company is focused on developing small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s pipeline product candidates are Friedreich ataxia and Myotonic dystrophy (CTG). Friedreich ataxia (FA) is a monogenic, autosomal recessive progressive disease. Myotonic dystrophy (DM1) is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.